Lipidomics in drug development.
Lipidomics in drug development.
复制标题
DOI：
10.1016/j.ddtec.2015.03.002
复制
发表时间：
2015-06-01
期刊：
影响因子：
--
通讯作者：
Swinnen, Johannes V
中科院分区：
文献类型：
--
作者：
Dehairs, Jonas;Derua, Rita;Swinnen, Johannes V
许多人类病理学，包括常见病症如肥胖症、糖尿病、心血管疾病、癌症、炎性疾病和神经变性，涉及脂质代谢的变化。同样，越来越多的药物正在开发，直接或间接影响脂质代谢途径。代替经典和繁琐的放射化学分析，基于质谱（MS）的脂质组学的脂质谱分析在药物开发过程的沿着的几个步骤中作为伴随诊断具有巨大的潜力。在这篇综述中，我们描述了一些典型的脂质组学设置，并说明这些技术如何可以在目标发现，化合物筛选，体外和体内临床前测试，药物的毒性测试，预测和监测的反应。
Numerous human pathologies, including common conditions such as obesity, diabetes, cardiovascular disease, cancer, inflammatory disease and neurodegeneration, involve changes in lipid metabolism. Likewise, a growing number of drugs are being developed that directly or indirectly affect lipid metabolic pathways. Instead of classical and cumbrous radiochemical analyses, lipid profiling by mass spectrometry (MS)-based lipidomics holds great potential as companion diagnostic in several steps along the drug development process. In this review we describe some typical lipidomics set-ups and illustrate how these technologies can be implemented in target discovery, compound screening, in vitro and in vivo preclinical testing, toxicity testing of drugs, and prediction and monitoring of response.